Novo Nordisk’s stock dropped 5.6% as the S&P 500 and Nasdaq rose. The Danish drugmaker’s Phase II trial on using semaglutide to treat Alzheimer’s failed to show progress despite positive signs on certain biomarkers. Novo faces competition in obesity and weight loss markets, impacting stock performance.

The Motley Fool Stock Advisor team did not include Novo Nordisk in their 10 best stocks to buy now. Their top picks have historically outperformed the S&P 500 significantly. Novo investors face challenges, but long-term potential exists. Stock Advisor’s average return is 981%, beating the S&P 500’s 187%.

Read more at Yahoo Finance: Why Novo Nordisk Stock Sank 5.6% Today